Aclaris Therapeutics (ACRS) Common Equity (2017 - 2025)
Historic Common Equity for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $120.1 million.
- Aclaris Therapeutics' Common Equity fell 772.26% to $120.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.1 million, marking a year-over-year decrease of 772.26%. This contributed to the annual value of $155.6 million for FY2024, which is 103.39% down from last year.
- As of Q3 2025, Aclaris Therapeutics' Common Equity stood at $120.1 million, which was down 772.26% from $131.7 million recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' Common Equity peaked at $235.8 million during Q2 2022, and registered a low of $112.3 million during Q1 2021.
- In the last 5 years, Aclaris Therapeutics' Common Equity had a median value of $157.2 million in 2023 and averaged $169.5 million.
- In the last 5 years, Aclaris Therapeutics' Common Equity skyrocketed by 43139.58% in 2021 and then plummeted by 2888.72% in 2023.
- Aclaris Therapeutics' Common Equity (Quarter) stood at $197.3 million in 2021, then rose by 0.14% to $197.6 million in 2022, then fell by 20.46% to $157.2 million in 2023, then fell by 1.03% to $155.6 million in 2024, then decreased by 22.79% to $120.1 million in 2025.
- Its Common Equity was $120.1 million in Q3 2025, compared to $131.7 million in Q2 2025 and $144.1 million in Q1 2025.